Lactobacillus reuteri V3401 Reduces Inflammatory Biomarkers and Modifies the Gastrointestinal Microbiome in Adults with Metabolic Syndrome: The PROSIR Study
- 2019-07-31
- Nutrients 11(8)
- C. Tenorio-Jiménez
- M. Martínez-Ramírez
- I. Del Castillo-Codes
- C. Arraiza-Irigoyen
- M. Tercero-Lozano
- José Camacho
- N. Chueca
- Federico García
- J. Olza
- J. Plaza-Díaz
- L. Fontana
- M. Olivares
- Á. Gil
- C. Gómez-Llorente
- PubMed: 31370223
- DOI: 10.3390/nu11081761
Abstract
Previous studies have reported that probiotics may improve clinical and inflammatory parameters in patients with obesity and metabolic syndrome (MetS). Lactobacillus (L.) reuteri V3401 has shown promising results on the components of MetS in animal studies. We aimed to evaluate the effects of L. reuteri V3401 together with healthy lifestyle recommendations on adult patients with MetS.
Methods: We carried out a randomized, crossover, placebo-controlled, single-center trial in which we included 53 adult patients newly diagnosed with MetS. Patients were block randomly allocated by body mass index (BMI) and sex to receive a capsule containing either the probiotic L. reuteri V3401 (5 × 109 colony-forming units) or a placebo once daily for 12 weeks. Anthropometric variables, biochemical and inflammatory biomarkers, as well as the gastrointestinal microbiome composition were determined.
Results: There were no differences between groups in the clinical characteristics of MetS. However, we found that interleukin-6 (IL-6) and soluble vascular cell adhesion molecule 1 (sVCAM-1) diminished by effect of the treatment with L. reuteri V3401. Analysis of the gastrointestinal microbiome revealed a rise in the proportion of Verrucomicrobia.
Conclusions: Consumption of L. reuteri V3401 improved selected inflammatory parameters and modified the gastrointestinal microbiome. Further studies are needed to ascertain additional beneficial effects of other probiotic strains in MetS as well as the mechanisms by which such effects are exerted.
Keywords: Lactobacillus reuteri V3401; gastrointestinal microbiome; metabolic syndrome; obesity; probiotics.
Research Insights
| Supplement | Health Outcome | Effect Type | Effect Size |
|---|---|---|---|
| Lactobacillus reuteri | Modification of Gastrointestinal Microbiome | Beneficial | Moderate |
| Lactobacillus reuteri | Reduced Inflammation Levels | Beneficial | Moderate |
| Lactobacillus reuteri HA-188 | Modification of Gastrointestinal Microbiome | Beneficial | Moderate |
| Lactobacillus reuteri HA-188 | Reduced Inflammatory Markers | Beneficial | Moderate |
| Lactobacillus reuteri LRE02 | Modification of Gastrointestinal Microbiome | Beneficial | Moderate |
| Lactobacillus reuteri LRE02 | Reduced Inflammatory Markers | Beneficial | Moderate |
| Lactobacillus reuteri MAK02L14R | Modification of Gastrointestinal Microbiome | Beneficial | Moderate |
| Lactobacillus reuteri MAK02L14R | Reduced Inflammatory Markers | Beneficial | Moderate |
| Lactobacillus reuteri NCIMB 30242 | Altered Gastrointestinal Microbiome Composition | Beneficial | Moderate |
| Lactobacillus reuteri NCIMB 30242 | Reduced Inflammatory Markers | Beneficial | Moderate |
| Lactobacillus reuteri Osfortis | Increased Proportion of Verrucomicrobia in Gastrointestinal Microbiome | Beneficial | Large |
| Lactobacillus reuteri Osfortis | Reduced Interleukin-6 Levels | Beneficial | Moderate |
| Lactobacillus reuteri Osfortis | Reduced Soluble VCAM-1 Levels | Beneficial | Moderate |
| Lactobacillus reuteri UALre-16 | Modification of Gastrointestinal Microbiome | Beneficial | Moderate |
| Lactobacillus reuteri UALre-16 | Reduced Inflammatory Markers | Beneficial | Moderate |